Mereo BioPharma Group PLC (MREO)
3.72
+0.04
(+1.09%)
USD |
NASDAQ |
Nov 22, 16:00
3.725
0.00 (0.00%)
After-Hours: 20:00
Mereo BioPharma Group Cash from Operations (Quarterly): -7.519M for Sept. 30, 2024
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | -7.519M |
| June 30, 2024 | -7.904M |
| March 31, 2024 | -7.991M |
| December 31, 2023 | -6.789M |
| Date | Value |
|---|---|
| September 30, 2023 | 2.659M |
| June 30, 2023 | -7.754M |
| March 31, 2023 | -9.248M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-9.248M
Minimum
Mar 2023
2.659M
Maximum
Sep 2023
-6.364M
Average
-7.754M
Median
Jun 2023
Cash from Operations (Quarterly) Benchmarks
| TC BioPharm (Holdings) PLC | -3.055M |
| NuCana PLC | -1.446M |
| Biodexa Pharmaceuticals PLC | -- |
| Adaptimmune Therapeutics PLC | -54.45M |
| DBV Technologies SA | -22.46M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Financing (Quarterly) | -0.594M |
| Free Cash Flow | -30.90M |
| Free Cash Flow Per Share (Quarterly) | -0.0488 |
| Free Cash Flow Yield | -5.76% |